Qatari authorities announced on Saturday, November 7, the recall of all batches of Isotears-Plus eye drops currently on sale due to manufacturing defects.
The Ministry of Health of Qatar appealed to citizens who purchased the product, strongly urging them to immediately stop using it. It was emphasized that this action reflects a commitment to ensuring patient safety and high quality of pharmaceutical products in the market. The reason for the recall was 'critical observations related to data integrity and sterile processing at the production facility.'
Isotears-Plus is a lubricating eye drop solution designed to provide temporary relief from burning, irritation, and discomfort caused by dry eyes or environmental exposure.
This announcement followed three days after the recall of all batches of another eye medication, Clasgen 0.05%, for similar reasons. On November 4, authorities cited 'observations at the production site concerning data integrity and sterile manufacturing processes' as the basis for the decision.
These eye drops are prescription immunomodulatory agents used to treat chronic dry eye (keratoconjunctivitis sicca) by reducing surface inflammation and promoting the restoration of natural tear production. At the time of publication, it was not clear whether both recall decisions were related.


